Cornea/External Disease News

NEW ORLEANS — In this Healio Video Perspective from the Eyecelerator meeting, Michelle Senchyna, PhD, vice president of clinical development and medical affairs at Aerie, discusses phase 2b study results for AR-15512 in dry eye disease.

NEW ORLEANS — With an international shortage of donor corneal tissue, a procedure that uses a patient’s own cells to repair the endothelium may be a viable alternative for transplantation, according to an expert here.

Reproxalap achieved the primary endpoint of improved ocular redness in patients with dry eye disease in a phase 2 clinical trial, according to a press release from Aldeyra Therapeutics.

The FDA has issued a new safety concern communication warning of the dangers associated with getting hand sanitizer in the eyes, reporting more than 3,500 cases of ocular exposure to alcohol-based hand sanitizers with adverse events.

Fatty infiltration of the levator muscle has been studied widely as a contributing factor in the pathogenesis of congenital, acquired and involutional ptosis.

In this video, related to the ESCRS meeting, Jorge L. Alió, MD, PhD, speaks about corneal regeneration using stem cells, a new technique at the early stages of development that might become an alternative to corneal transplantation.

Allergan, an AbbVie company, announced the FDA approval of the eye drop, Vuity, for the treatment of presbyopia.

A pair of costume contact lenses may complete a Halloween look, but lenses obtained without a prescription can be dangerous.

Teprotumumab is effective in reducing proptosis in people with thyroid eye disease more than 2 years after treatment, and initial nonresponders to teprotumumab may benefit from a second series of infusions, according to a speaker.

Treatment for thyroid eye disease should be personalized, with joint input from endocrinologists and ophthalmologists, according to two speakers.